MEDICA

MEDICA S.p.A.
Via Degli Artigiani, 7
41036 MEDOLLA
MODENA - ITALY

Tel. 0535 51159
Fax 0535 52605
e-mail: info@medica.it
home page: www.medica.it

International:
Tel. +39 0535 51159
Fax +39 0535 52605

Press release

MEDICA ADMITTED TO TRADING ON EURONEXT GROWTH MILAN

PLACEMENT SUCCESSFULLY COMPLETED WITH A DEMAND EQUAL TO 7.6x THE OFFERED AMOUNT

OFFER PRICE SET AT € 27.00 AND CAPITALIZATION OF € 114 MILLION

Start of trading scheduled for November 3rd, 2021

Medolla (MO), 1 November 2021 - Medica, fully integrated Italian biomedical and MedTech group with a strong international footprint, announces that the admission to trading of Medica's ordinary shares was obtained today by Borsa Italiana S.p.A., on the Euronext Growth Milan market, multilateral trading system organized and managed by Borsa Italiana S.p.A..

Admission follows the completion of placement of a total of 847,650 ordinary shares (including overallotment and greenshoe option) for coutervalue of 22.9 million Euros, raising demand for more than 174 million euros based on the offering price, about 7.6 times the offer. Start of trading is set for Wednesday, November 3rd, 2021.

Luciano Fecondini, Founder and Chairman of Medica, commented: We are certainly proud of the results of the IPO process. Thanks to the listing, we receive fresh equity to carry on innovative projects of significant size and to accelerate our growth through focused and synergic acquisitions. We welcome the presence also of international investors among new shareholders, in line with our international footprint. Listing on Euronext Growth Milan is a first step towards an ambitious, long-term vision, being aware of our growth potential both in the medical and water purification fields.

<u>Placement</u>
The placement concerned (i) 685,150 newly issued shares, in addition to (ii) 62,500 existing shares offered for sale by the shareholder Andrea Bocchi and (iii) 100,000 shares deriving from the exercise of the over-allotment and greenshoe options granted by the shareholders Luciano Fecondini and Andrea Bocchi. Thus, the total offer concerned a total of 847,650 ordinary shares, corresponding to22.9 million euros.

The offer has met with a strong interest among the Italian and international financial community, with a request for the Offer Price exceeding 174 million Euros from primary qualified investors, mainly "long only". Based on the offering price, the total demand is about 7.6 times the supply and comes for about 42% from foreign investors.

The placement price was set at Euro 27.00 per share, at the top of the range; based on the offering price, the market capitalization of Medica is Euro 114 million at the beginning of trading, including the capital increase of Euro 18.5 million. The Free Float of the Company will be equal to approximately 20.1% of the share capital, assuming the full exercise of the greenshoe option.

As a result of the placement, Medica's share capital will consist of 4,223,250 ordinary shares with no par value.

Below is the makeup of the shareholders as a result of the placement:

Shareholders	n. Shares post OPVS	% of share capital with right of vote	n. Share in case of full exercise of the Greenshoe Option	% of share capital with right of vote
Luciano Fecondini	2,476,670	58.64%	2,426,670	57.46%
Andrea Bocchi	998,930	23.65%	948,930	22.47%
Free Float	747,650	17.70%	847,650	20.07%

Identification codes

The following identification codes have been assigned to the Ordinary Shares:
• Alphanumeric Code: MDC
• ISIN Code: IT0005460149

Other Information

For the distribution of regulated information, Medica will use the 1INFO-SDIR system (www.1info.it), managed by Computershare S.p.A. with registered office in Milan, Via Lorenzo Mascheroni n. 19 and authorized by CONSOB.

Mr. Giovanni Plasmati will cover the role of Investor Relations Manager of Medica.

In the admission to trading on Euronext Growth Milan Medica is assisted by IMI - Intesa Sanpaolo (Global Coordinator & Joint Bookrunner), CFO SIM (Joint Bookrunner and Euronext Growth Advisor), DLA Piper (Issuer's Law Firm), LCA Studio Legale (Joint Bookrunner Law Firm), Epyon (Advisor for Financial Due Diligence, Non-Accounting Data and Management Control System), EY (Independent Audit Firm), Hermes (Business Plan Advisor and Advisor for Tax Due Diligence). The Admission Document is available at the registered office and on the www.medica.it website, in the Investors section.

Medica profile

Medica Group is operating since 1985 in the biomedical district of Mirandola (Italy). Development of innovative products for blood purification has always been company's core business. Thanks to the activity of two extremely dynamic R&D groups (medical equipment, membranes and disposable), the Group competes successfully in several markets, namely:

- **Medical** (dialysis, CRRT, ECCO2, Apheresis, DFPP, CHF, HIPEC, pre-transplant organ perfusion, bioregenerative medicine, gastroenterology, urodynamics, oxygen humidification).
- **Microbiological purification of water**
- **Industrial automation** for the biomedical sector.

R&D focus has been integrated over the years with a highly automated production systems in five different facilities, four in Italy and one in Tunisia, and two commercial entities (in US and in China).

The key success factors of the Group are:

- **extrusion of hollow fiber membranes** for hemofiltration, plasmapheresis, cascade filtration, oxygen humidification, ultrafiltration and microfiltration of water
- **vertical integration,** proved by the ability to manage not only the design and development of medical disposables and equipment, and the development of the automation technologies required for their production as well.
- **International recognition with significant share of export** (69% of revenues in 2020), with sales in over 60 countries.

Medica group closed the consolidated financial statement for the year 2020 with revenues of 44.1 million euros (34.7 million euros in 2019), EBITDA of 9.5 million euros (7.7 million euros in 2019), EBIT of 5.6 million euros (3.6 million euros in 2019) and net profit of 3.8 million euros (2.8 million euros in 2019). In the first 6 months of 2021, Medica realized revenues of 20.3 million euros and an EBITDA of 4.2 million euros.

For information:
Investor Relations Medica
Giovanni Plasmati
(+39) 0535 51159
giovanni.plasmati@medica.it

Euronext Growth Advisor
CFO SIM S.p.A.
(+39) 02 303431
ecm@cfosim.com